scholarly journals GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy*

HIV Medicine ◽  
2004 ◽  
Vol 5 (5) ◽  
pp. 352-359 ◽  
Author(s):  
P Bossi ◽  
G Peytavin ◽  
H Ait-Mohand ◽  
C Delaugerre ◽  
N Ktorza ◽  
...  
AIDS ◽  
2002 ◽  
Vol 16 (5) ◽  
pp. 727-736 ◽  
Author(s):  
Jean-Luc Meynard ◽  
Muriel Vray ◽  
Laurence Morand-Joubert ◽  
Esther Race ◽  
Diane Descamps ◽  
...  

2003 ◽  
Vol 37 (5) ◽  
pp. 708-713 ◽  
Author(s):  
S. M. Badri ◽  
O. M. Adeyemi ◽  
B. E. Max ◽  
B. M. Zagorski ◽  
D. E. Barker

AIDS ◽  
2014 ◽  
Vol 28 (15) ◽  
pp. 2231-2239 ◽  
Author(s):  
Karin J. Metzner ◽  
Alexandra U. Scherrer ◽  
Viktor von Wyl ◽  
Jürg Böni ◽  
Sabine Yerly ◽  
...  

2011 ◽  
Vol 9 (1) ◽  
pp. 14 ◽  
Author(s):  
Jan Fehr ◽  
Tracy R Glass ◽  
S�verine Louvel ◽  
Fran�ois Hamy ◽  
Hans H Hirsch ◽  
...  

2004 ◽  
Vol 48 (8) ◽  
pp. 3122-3126 ◽  
Author(s):  
Soo-Yon Rhee ◽  
Tommy Liu ◽  
Jaideep Ravela ◽  
Matthew J. Gonzales ◽  
Robert W. Shafer

ABSTRACT In a sample of 6,156 sequences from 4,183 persons, the top 30 patterns of protease inhibitor, nucleoside reverse transcriptase (RT) inhibitor, and nonnucleoside RT inhibitor mutations accounted for 55, 46, and 66%, respectively, of sequences with drug resistance mutations. Characterization of the phenotypic and clinical significance of these common patterns may lead to improved treatment recommendations for a large proportion of patients for whom antiretroviral therapy is failing.


Sign in / Sign up

Export Citation Format

Share Document